Repeat-Dose Study of Bavituximab in Patients With Chronic Hepatitis C

Inclusion Criteria: * At least 18 years of age * Chronic Hepatitis C infection based on history and detectable serum HCV RNA including treatment naïve subjects as well as subjects who are partial responders and/or relapsers to prior therapy(ies) * All genotypes of HCV acceptable * Complete Blood Counts within normal limits * Normal renal function (serum creatinine within normal limits) * Normal coagulation profile (PT/INR and aPTT within normal limits) * Patients of reproductive potential must agree to use an approved form of barrier contraception. Female patients must have a negative serum pregnancy test at prestudy (not applicable to patients with bilateral oophorectomy and/or hysterectomy or to those patients who are postmenopausal) Exclusion Criteria: * Prior exposure to any chimeric antibody * Any other cause of liver disease other than chronic hepatitis C, such as autoimmune or alcoholic liver disease. * Decompensated clinical liver disease, including a history of prolonged clotting times, hypoalbuminemia, encephalopathy, treatment for elevated ammonia levels, or ascites * Any evidence of clinically significant bleeding defined as gross hematuria, hemoptysis, or gastrointestinal bleeding * Known history of bleeding diathesis or coagulopathy (e.g., von Willebrand Disease or Hemophilia) * Any history of thromboembolic events \[e.g., deep vein thrombosis (DVT) or pulmonary thromboembolism (PE)\] including central venous catheter-related thrombosis within the past 12 months * Concurrent therapy with oral or parenteral anticoagulants * Concurrent hormone therapy (i.e., estrogen contraceptives, hormone replacement, anti-estrogen) * Antiviral therapy within 4 weeks of day 0 * Investigational therapy within 4 weeks of day 0 * Major surgery within 4 weeks of day 0 * Pregnant or nursing women * Uncontrolled intercurrent disease (e.g., diabetes, hypertension, thyroid disease) * Any history of angina pectoris, coronary artery disease or cerebrovascular accident, or transient ischemic attack * A history of any condition requiring anti-platelet therapy with the exception of general cardiovascular prophylaxis with aspirin * A history of any condition requiring treatment (past or current) with coumarin-type agents * Cardiac arrhythmia requiring medical therapy * Serious non-healing wound (including wound healing by secondary intention, ulcer, or bone fracture) * Requirement for chronic daily treatment with NSAIDs, antiplatelet drugs (e.g., phosphodiesterase inhibitors, adenosine diphosphate receptor antagonists), or steroids * Cancer, autoimmune disease or any disease or concurrent therapy known to cause significant alteration in immunologic function * Known chronic infection with HIV or HBV